ArticleOncology letters2026
Association between fibroblast activation protein α expression and immune environment in gastric cancer.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Spatial Fibroblast-Macrophage Niches in Gastric Cancer: Mechanisms of Immune Exclusion, Therapeutic Resistance, and Targeted Intervention.OncoTargets and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor stroma serves an important role in cancer progression. However, the role of fibroblast activation protein α (FAP), a subpopulation marker of cancer-associated fibroblasts (CAFs), remains poorly understood, especially in gastric cancer. The present study investigated the role of FAP-positive CAFs in gastric cancer prognosis and immune environment. The retrospective study included patients with gastric cancer who underwent curative resection. The tumor-stroma ratio (TSR) and FAP expression status were evaluated using immunohistochemistry, after which their associations with recurrence-free survival (RFS) were investigated. In addition, immune cell infiltration was evaluated, including T cells, regulatory T cells (Tregs) and M2 macrophages, using immunohistochemistry, and its association with TSR or FAP status was analyzed. Among the 128 eligible patients, 29 (23%) had low TSR, whereas 39 (30%) were FAP-positive. No significant association was observed between TSR and FAP status (P=0.596). The low TSR group and FAP-positive group showed significantly worse survival than the high TSR group and FAP-negative group (log-rank P=0.004, P=0.011, respectively). Subsequently, a Cox multivariate analysis for RFS identified that FAP positivity was an independent factor for poor prognosis (P=0.009) but low TSR was not (P=0.088). FAP-positive patients had a higher tumor infiltrating FOXP3
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.